Advancing Novel Biotherapeutics Since 1995®

Investor Relations

Dyax is a fully integrated biopharmaceutical company focused on developing and commercializing products for unmet medical needs. We currently market a product for the treatment of acute attacks of hereditary angioedema (HAE), a rare genetic disease (to learn more, click here). We also have an investigational drug candidate in development for the prevention of HAE attacks (to learn more, click here).

Both our commercial product and drug candidate in development were identified using Dyax’s proprietary phage display technology. We have broadly licensed this technology and have a portfolio of product candidates being developed by our licensees that we refer to as the Licensing and Funded Research Portfolio (LFRP). This portfolio includes one approved product for which we receive royalties. Additionally, there are multiple product candidates in various stages of clinical development for which we are eligible to receive future milestones and/or royalties (to learn more, click here).

More »Stock Quote

DYAX (Common Stock)
Exchange NASDAQ (US Dollars)
Price $15.18
Change (%) 0.98 (-6.06)%
Volume 863,100
Data as of Jan 28, 2015 4:00 PM ET
Delayed at least 20 minutes. Provided by eSignal.
Refresh Quote

More »Recent Releases

Date Title
Dec 3, 2014 Dyax Corp. to Participate in the 25th Annual Oppenheimer Healthcare Conference
Nov 18, 2014 Dyax Corp. Recognized as a "Top Place to Work" by The Boston Globe
Nov 3, 2014 Dyax Corp. Announces Expansion of Phase 1b Clinical Trial for DX-2930
Oct 28, 2014 Dyax Corp. Announces Third Quarter 2014 Financial Results

More »Calendar of Events

Details on upcoming events are not yet available.

More » Event Archives

Dec 10, 2014 Oppenheimer & Co. Inc. 25th Annual Healthcare Conference
Oct 28, 2014 Dyax Corp. 3Q 2014 Earnings Call
Oct 1, 2014 Leerink Partners Rare Disease Roundtable
Jul 29, 2014 Dyax Corp. 2Q 2014 Earnings Call

Featured Financial Reports

Filing Date Title Type Size
Nov 3, 2014 10-Q View HTML View PDF 530.9 KB Add to Briefcase
Dec 31, 2013 2013 Annual Report PDF  508.9 KB Add to Briefcase
Add to Briefcase = add file to Briefcase

You are now leaving Dyax.com.

The web site you are about to visit is . It is neither owned nor controlled by Dyax Corp. Dyax is not responsible for the content, products or services on this site.

Do you wish to continue?